Lamivudine/nevirapine/stavudine
| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Stavudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Triomune, others |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[1] It contains lamivudine, nevirapine, and stavudine.[1] It is either used by itself or along with other antiretrovirals.[1] It is taken by mouth twice a day.[1]
It is on the World Health Organization's List of Essential Medicines.[2] As of 2015, it is not commercially available in the United States.[3]
- ^ a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Kasper DL, Fauci AS, Hauser S, Longo D, Jameson JL, Loscalzo J (2015). Harrison's Principles of Internal Medicine 19/E (Vol.1 & Vol.2). McGraw Hill Professional. p. 1277. ISBN 9780071802161. Archived from the original on 2016-12-20.